Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E106.14 EPS (ttm)5.13 Insider Own1.10% Shs Outstand104.07M Perf Week-6.05%
Market Cap56.67B Forward P/E36.60 EPS next Y14.88 Insider Trans-14.46% Shs Float76.85M Perf Month-2.77%
Income591.20M PEG5.30 EPS next Q3.41 Inst Own72.80% Short Float4.00% Perf Quarter6.04%
Sales3.81B P/S14.88 EPS this Y-19.40% Inst Trans-0.90% Short Ratio3.51 Perf Half Y7.00%
Book/sh31.90 P/B17.07 EPS next Y18.38% ROA13.30% Target Price625.84 Perf Year30.85%
Cash/sh8.61 P/C63.26 EPS next 5Y20.03% ROE19.50% 52W Range383.87 - 605.93 Perf YTD32.72%
Dividend- P/FCF91.37 EPS past 5Y41.20% ROI12.50% 52W High-10.14% Beta0.95
Dividend %- Quick Ratio3.40 Sales past 5Y49.40% Gross Margin91.00% 52W Low41.84% ATR15.79
Employees2925 Current Ratio3.60 Sales Q/Q56.70% Oper. Margin32.30% RSI (14)46.33 Volatility2.62% 2.74%
OptionableYes Debt/Eq0.12 EPS Q/Q154.90% Profit Margin15.50% Rel Volume0.96 Prev Close563.10
ShortableYes LT Debt/Eq0.12 EarningsNov 04 BMO Payout0.00% Avg Volume876.32K Price544.50
Recom2.00 SMA20-3.94% SMA502.07% SMA2007.53% Volume844,761 Change-3.30%
Nov-05-15Reiterated RBC Capital Mkts Outperform $665 → $676
Oct-02-15Downgrade Morgan Stanley Overweight → Equal-Weight $593
Sep-01-15Initiated Raymond James Outperform $615
Aug-31-15Downgrade Chardan Capital Markets Buy → Neutral $565
Aug-10-15Reiterated ROTH Capital Neutral $495 → $527
Aug-06-15Reiterated Argus Buy $560 → $660
Aug-05-15Reiterated UBS Sell $500 → $565
Aug-05-15Reiterated RBC Capital Mkts Outperform $570 → $665
Aug-05-15Reiterated Canaccord Genuity Buy $600 → $700
Aug-05-15Reiterated Barclays Equal Weight $460 → $595
Aug-04-15Reiterated Brean Capital Buy $525 → $659
Aug-03-15Reiterated Leerink Partners Outperform $559 → $630
Jul-27-15Reiterated RBC Capital Mkts Outperform $560 → $570
Jul-22-15Initiated Northland Capital Market Perform $560
Jul-20-15Reiterated RBC Capital Mkts Outperform $550 → $560
Jul-13-15Reiterated Deutsche Bank Buy $455 → $650
Jun-15-15Reiterated RBC Capital Mkts Outperform $543 → $550
Jun-10-15Reiterated Chardan Capital Markets Buy $560 → $565
May-20-15Reiterated Canaccord Genuity Buy $525 → $600
May-20-15Reiterated Argus Buy $500 → $560
Nov-30-15 03:04PM  Stocks Work Off Losses; Lululemon Further Weakens at Investor's Business Daily
11:58AM  Stocks Trade Lower At Midday; Cambrex Hits New All-Time High at Investor's Business Daily
10:25AM  The European Commission Approved Novartiss Entresto
Nov-29-15 11:38AM  Is Thermo Fisher Scientific Inc. (TMO) Going to Burn These Hedge Funds? at Insider Monkey
Nov-25-15 07:39PM  Biotech ETFs Beat The Gloom; Gold At Lows at Investor's Business Daily
07:00PM  [video]Jim Cramer's 'Mad Money' Recap: How to Become an Even Better Investor at TheStreet
Nov-24-15 01:00AM  Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled PR Newswire
Nov-23-15 05:30PM  3 Stocks to Buy and Hold for the Next Decade at Motley Fool
04:06PM  CVS' Amgen Pick 'Raises The Bar' For Regeneron, Sanofi at Investor's Business Daily
02:53PM  Is The Dow Chemical Company (DOW) A Good Stock To Buy? at Insider Monkey
12:47PM  Mylan Topped Large-Caps with New Launches, Share Repurchase Plan
11:33AM  Uh Oh, CVS Prefers Amgen's Cholesterol Drug to Regeneron's at
11:03AM  Weekly CFO Sells Highlights: Facebook, Fitbit, Regeneron Pharmaceuticals
08:00AM  CVS chooses Amgen's new cholesterol drug over competitor Reuters
08:00AM  CVS Makes Exclusive Deal to Cover Amgens Cholesterol Drug at Bloomberg
Nov-21-15 06:16PM  WEEKEND VIDEO: Market Positives and Negatives
08:00AM  5 Things Amgen, Inc. Wants You to Know at Motley Fool
Nov-20-15 03:53PM  How Has PBE Performed in the Market This Year?
01:31PM  November Rundown of the Fidelity Growth Company Fund
09:59AM  Biotech: Let It Bleed at
Nov-19-15 04:15PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
Nov-18-15 11:16AM  Biotech: 'We Would Hold Off on Any New Purchases' at
08:36AM  Sanofi and Regeneron Hit Another Bullseye at Motley Fool
Nov-16-15 01:27PM  Stocks Strengthen In Afternoon; Biotechs Weak at Investor's Business Daily
09:18AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Nov-14-15 07:21AM  These 2 Companies Could Revolutionize Heart Disease Prevention at Motley Fool
Nov-13-15 06:24PM  Regeneron Tests Buy Point As New Drug Shows Promise at Investor's Business Daily
04:30PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
02:16PM  Merck continuing study of cholesterol drug in new class
Nov-12-15 06:30PM  Gilead, Regeneron Stocks Weather Drug Pricing Furor at Investor's Business Daily
03:14PM  The high-flying health-care sector is now slowing dramatically at MarketWatch
11:27AM  Regeneron Recovers From Clinton Biotech Beat Down at Investor's Business Daily
10:30AM  Regeneron In Buy Zone As Arthritis Drug Shows Promise
Nov-11-15 10:45AM  Alnylam, Medicines Co cholesterol drug effective for 6 months-study Reuters
Nov-10-15 06:01PM  Sanofi and Regeneron Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015 PR Newswire
06:00PM  Regeneron and Sanofi Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015 PR Newswire
02:58PM  Why Aegerion Pharmaceuticals Is Crashing Today at Motley Fool
08:05AM  Vertex Reported Its 3Q15 Earnings: Stock Rose 5%
Nov-09-15 01:49PM  What Does 2016 Hold for This Closely-Watched Biotech ETF? at Motley Fool
01:22PM  Regeneron Pharmaceuticals, Inc. Earnings Q3, 2015
10:00AM  Sanofi SA and Regeneron Pharmaceuticals Inc IR Thematic Call on Sarilumab scheduled for 10:00 am ET today
09:31AM  Sivik Global Healthcares Top Biotech Stock Picks For Q4 at Insider Monkey
Nov-08-15 07:08AM  Sanofi and Regeneron Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting PR Newswire
07:00AM  Regeneron and Sanofi Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting PR Newswire
Nov-05-15 11:08AM  An Overview of PTHs Pharmaceutical and Biotechnology Holdings
08:45AM  New Survey of U.S. Adults with Diabetes Reveals Less than Half Understand Their Risk for Vision Loss PR Newswire
08:00AM  Sanofi and Regeneron to Present Results from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2015 PR Newswire
Nov-04-15 08:31PM  Edited Transcript of REGN earnings conference call or presentation 4-Nov-15 1:30pm GMT
03:42PM  The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings
03:41PM  Regeneron Q3 Beats Views, But Praluent Launch Slow at Investor's Business Daily
02:14PM  Regeneron Misses on Q3 Earnings, Eylea 2015 View Upped
12:27PM  Regeneron's 3Q EPS Beat Can't Lift the Stock; Shares Down 4.5% at
11:27AM  Jim Cramer -- DSW Gets the Boot; Regeneron's Earnings Are Solid at TheStreet
09:52AM  Cramer's Stop Trading: DSW & REGN
08:30AM  Regeneron Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today
08:10AM  Regeneron (REGN) Misses on Q3 Earnings, Revenues In Line
08:06AM  Early movers: TWX, KORS, CBS, LL, HSIC, TSLA & more at CNBC
07:17AM  [$$] Regeneron Results Soar on Eye-Treatment Sales at The Wall Street Journal
07:07AM  Q3 2015 Regeneron Pharmaceuticals Inc Earnings Release - Before Market Open
07:06AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
06:41AM  Regeneron beats Street 3Q forecasts
06:38AM  Regeneron revenue jumps 57 pct as Eylea sales surge
06:30AM  Regeneron Reports Third Quarter 2015 Financial and Operating Results PR Newswire
Nov-03-15 05:02PM  Facebook, Whole Foods Lead Top Earnings To Watch Wed. at Investor's Business Daily
12:54PM  What to Watch When Regeneron Reports at
Nov-02-15 04:25PM  What's in Store for Regeneron (REGN) This Earnings Season?
02:38PM  Stocks Rally To Session Highs; Fitbit, Tesla Jump at Investor's Business Daily
01:19PM  M&A News Fuels More Gains; Celgene, Regeneron Lead Nasdaq 100 at Investor's Business Daily
Oct-31-15 08:02AM  Facebook, Visa To Carry IBD 50 Earnings To Peak at Investor's Business Daily
Oct-30-15 09:00AM  Regeneron Announces EU Approval of EYLEA® (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization PR Newswire
08:19AM  Why biotech could be on the verge of a rebound
Oct-29-15 04:25PM  Facebook Leads 5 L-T Growth Kings With Earnings On Tap at Investor's Business Daily
08:11AM  Boardroom Compensation Made This Man a Billionaire at Bloomberg
Oct-28-15 07:12AM  [$$] Regeneron's Q3 Could Top Projections at
Oct-27-15 04:50PM  Aegerion (AEGR) Q3 Earnings Preview: What's in the Cards?
01:25PM  Regeneron Pharmaceuticals, Inc. Value Analysis (NASDAQ:REGN) : October 27, 2015
06:20AM  Jim Cramers Plan for This Market, Part 2 -- Shun These Risky Businesses at TheStreet
Oct-23-15 09:30AM  Regeneron Announces Presentation at the 24th Annual Credit Suisse Healthcare Conference PR Newswire
Oct-22-15 03:52PM  Hurricane Hillary Shifts Left, Slamming More Stocks at Investor's Business Daily
Oct-20-15 10:24AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : October 20, 2015
Oct-19-15 10:27AM  One Stage: $700 Billion Of Pharma Firepower at Forbes
07:42AM  Eli Lilly's Failure Is a Success for These Companies at Motley Fool
Oct-18-15 01:02PM  3 Biotechs Growing Faster Than Apple at Motley Fool
Oct-15-15 04:34PM  Facebook Among 4 Techs With Stellar Long-Term Earnings at Investor's Business Daily
Oct-14-15 02:45PM  Regeneron Pharmaceuticals, Inc.: A look at fundamentals
09:47AM  Pullbacks Make Better Buys Of Amgen and Four Biotech Stocks at Forbes
Oct-13-15 12:00PM  Regeneron Pharmaceuticals (REGN) Stock is the 'Chart of the Day' at TheStreet
Oct-12-15 08:06PM  Merck cholesterol drug's odds dim after Lilly failure
07:00PM  Cramer: Buy these stocks for the rest of 2015
04:31PM  Indexes Close Up Across The Board; Facebook Gains, But Twitter Falls at Investor's Business Daily
04:15PM  Energy Sector Retreated while Healthcare Sector Led on October 9
03:40PM  Winners and Losers of Eli Lilly's CETP Drug Failure at Motley Fool
03:06PM  4 Unusual-Volume Stocks to Trade for Breakouts at TheStreet
02:07PM  Lilly halts heart drug development
01:44PM  Stocks Near Flatline; Bad News for Lilly Is Good News For Regeneron at Investor's Business Daily
12:54PM  Regeneron Stock Pops But Hits Resistance At 50-Day
11:18AM  Lilly's Moat Still Intact After Halting Heart Drug Study at Morningstar
11:06AM  Lilly Loses Its Bloom; Amgen, Regeneron Blossom at
10:46AM  Jim Cramer -- Regeneron's Rally Is Going to Boost Biotechs at TheStreet
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration (AMD) and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes comprising familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. The company's trap-based clinical product candidates comprise EYLEA for the treatment of AMD and diabetic macular edema; and ZALTRAP for oncology. Its antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN727 for low-density lipoprotein cholesterol reduction and for the prevention of cardiovascular events; REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN668 for atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis; REGN2222 for respiratory syncytial virus; REGN1033 for skeletal muscle disorders; and REGN2176-3 and REGN910-3 antibodies for use in ophthalmology. The company is also developing REGN1908-1909, REGN1154, REGN1500, and REGN1193 antibody product candidates; REGN1400, REGN1979, and REGN2810 for oncology; and REGN475 for the treatment of pain. It has collaborations with Sanofi and Mitsubishi Tanabe Pharma Corporation; license and collaboration agreement with Bayer HealthCare; and Avalanche Biotechnologies, Inc., as well as Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SING GEORGE LDirectorNov 18Option Exercise19.693,00059,070115,772Nov 20 04:04 PM
VAGELOS P ROYChairman of the BoardNov 18Sale587.9017,24010,135,312334,611Nov 19 04:20 PM
SING GEORGE LDirectorNov 18Sale580.00500290,0004,500Nov 20 04:04 PM
SING GEORGE LDirectorNov 18Sale580.003,0001,740,000112,772Nov 20 04:04 PM
STAHL NEILEVP Research and DevelopmentNov 09Sale560.0522,10112,377,55922,029Nov 09 05:10 PM
STAHL NEILEVP Research and DevelopmentNov 06Sale563.0020,00011,260,06844,130Nov 09 05:10 PM
STAHL NEILEVP Research and DevelopmentNov 05Option Exercise28.29100,0002,828,50097,029Nov 09 05:10 PM
VAGELOS P ROYChairman of the BoardNov 03Sale580.233,9852,312,217351,851Nov 04 04:05 PM
VAGELOS P ROYChairman of the BoardNov 02Sale580.1813,2577,691,446355,836Nov 04 04:05 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriNov 02Sale571.6143,34824,778,125543,348Nov 03 04:20 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriOct 30Option Exercise11.64182,8182,128,002682,818Nov 03 04:20 PM
BROWN MICHAEL SDirectorSep 21Option Exercise57.113,000171,3303,000Sep 22 02:39 PM
BROWN MICHAEL SDirectorSep 21Sale551.553,0001,654,6500Sep 22 02:39 PM
BAKER CHARLES ADirectorSep 17Option Exercise18.615,00093,05014,000Sep 18 04:06 PM
BAKER CHARLES ADirectorSep 17Sale550.005,0002,750,0009,000Sep 18 04:06 PM
SCHLEIFER LEONARD SPresident & CEOSep 02Option Exercise402.697,2262,909,83849,313Sep 03 04:59 PM
LAROSA JOSEPH JSVP General Counsel and SecretSep 01Option Exercise59.201,68999,98916,756Sep 02 04:04 PM
Powchik PeterSVP Clinical Development & RegAug 14Sale573.3823,48513,465,86615,821Aug 17 04:01 PM
Powchik PeterSVP Clinical Development & RegAug 13Option Exercise117.3360,3617,082,07046,299Aug 17 04:01 PM
POON CHRISTINE ADirectorAug 12Sale564.1611263,186790Aug 12 04:45 PM
POON CHRISTINE ADirectorAug 11Option Exercise273.67470128,6251,125Aug 12 04:45 PM
GILMAN ALFRED GDirectorAug 06Option Exercise57.115,000285,55013,912Aug 07 06:15 PM
Terifay Robert JSVP CommercialAug 06Sale588.9713,4237,905,78123,293Aug 07 06:14 PM
GILMAN ALFRED GDirectorAug 06Sale587.125,0002,935,6018,912Aug 07 06:15 PM
Tessier-Lavigne MarcDirectorAug 05Option Exercise57.115,000285,5506,187Aug 05 08:55 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 05Option Exercise270.435,0001,352,1509,745Aug 05 08:58 PM
Landry Robert ESVP Finance & CFOAug 05Option Exercise272.704,0001,090,80011,099Aug 06 09:00 PM
Terifay Robert JSVP CommercialAug 05Option Exercise30.6332,500995,47552,529Aug 07 06:14 PM
Landry Robert ESVP Finance & CFOAug 05Sale592.844,0002,371,3507,099Aug 06 09:00 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 05Sale585.535,0002,927,6484,945Aug 05 08:58 PM
Tessier-Lavigne MarcDirectorAug 05Sale590.265,0002,951,2751,187Aug 05 08:55 PM
GOLDSTEIN JOSEPH LDirectorAug 04Sale586.002,0001,172,00014,000Aug 05 10:03 AM
GOLDSTEIN JOSEPH LDirectorJul 15Sale550.002,0001,100,00016,000Jul 15 04:09 PM
GOLDSTEIN JOSEPH LDirectorJun 22Sale526.852,0001,053,70018,000Jun 22 05:02 PM
SING GEORGE LDirectorMay 27Option Exercise19.695,00098,450117,772May 29 04:19 PM
INGRAM ROBERT ALEXANDERDirectorMay 27Sale513.391,379707,9651,500May 27 04:02 PM
SING GEORGE LDirectorMay 27Sale515.005,0002,575,000112,772May 29 04:19 PM
McCorkle Douglas SVP Controller and Asst TreasurMay 22Option Exercise174.0113,4642,342,90217,481May 26 04:31 PM
INGRAM ROBERT ALEXANDERDirectorMay 22Option Exercise293.536,6671,956,9656,667May 27 04:02 PM
McCorkle Douglas SVP Controller and Asst TreasurMay 22Sale515.6013,0006,702,8004,481May 26 04:31 PM
GOLDSTEIN JOSEPH LDirectorMay 22Sale514.284,0002,057,10020,000May 26 04:30 PM
BROWN MICHAEL SDirectorMay 15Option Exercise57.115,000285,5505,000May 18 04:50 PM
BROWN MICHAEL SDirectorMay 15Sale495.005,0002,475,0000May 18 04:50 PM
Landry Robert ESVP Finance & CFOApr 08Option Exercise272.7010,0002,727,00015,000Apr 09 04:03 PM
BAKER CHARLES ADirectorMar 25Option Exercise18.615,00093,05014,000Mar 26 04:20 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 25Option Exercise59.203,097183,34215,067Mar 26 04:21 PM
BAKER CHARLES ADirectorMar 25Sale454.965,0002,274,7859,000Mar 26 04:20 PM
Aberman Michael SSVP Strategy Investor RelationMar 24Sale478.994,8432,319,73812,498Mar 25 04:07 PM
Aberman Michael SSVP Strategy Investor RelationMar 18Sale465.003,4421,600,54222,498Mar 19 04:05 PM
Aberman Michael SSVP Strategy Investor RelationMar 17Option Exercise24.0011,398273,55229,998Mar 19 04:05 PM
Terifay Robert JSVP CommercialMar 17Sale451.0110,9934,957,90720,029Mar 18 06:03 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 16Option Exercise59.2020,2811,200,63528,311Mar 17 04:57 PM
Terifay Robert JSVP CommercialMar 16Option Exercise30.6324,375746,60644,404Mar 18 06:03 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 16Sale450.0018,3118,239,95010,000Mar 17 04:57 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 27Sale416.243,0001,248,7204,481Feb 27 04:31 PM
Tessier-Lavigne MarcDirectorFeb 26Option Exercise50.913,000152,7304,187Feb 27 04:32 PM
Tessier-Lavigne MarcDirectorFeb 26Sale421.953,0001,265,8641,187Feb 27 04:32 PM
Aberman Michael SSVP Strategy Investor RelationFeb 24Sale418.483,3741,411,95218,600Feb 25 04:02 PM
Terifay Robert JSVP CommercialFeb 24Sale423.6711,1734,733,66520,029Feb 25 04:01 PM
Aberman Michael SSVP Strategy Investor RelationFeb 23Option Exercise30.637,500229,72526,100Feb 25 04:02 PM
Terifay Robert JSVP CommercialFeb 23Option Exercise30.6324,375746,60644,404Feb 25 04:01 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 23Sale427.829,4314,034,75418,705Feb 24 05:08 PM
RYAN ARTHUR FDirectorFeb 20Option Exercise125.7929,2503,679,49876,750Feb 23 04:06 PM
BROWN MICHAEL SDirectorFeb 20Option Exercise57.111,00057,1101,000Feb 23 04:07 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Option Exercise177.825,000889,1009,000Feb 20 04:44 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 20Option Exercise21.2520,000425,00038,705Feb 24 05:08 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Sale423.655,0002,118,2624,000Feb 20 04:44 PM
BROWN MICHAEL SDirectorFeb 20Sale422.721,000422,7200Feb 23 04:07 PM
RYAN ARTHUR FDirectorFeb 20Sale423.0129,25012,372,90847,500Feb 23 04:06 PM
Aberman Michael SSVP Strategy Investor RelationFeb 17Sale404.463,6921,493,26618,600Feb 18 04:40 PM
Aberman Michael SSVP Strategy Investor RelationFeb 13Option Exercise24.007,500180,00026,100Feb 18 04:40 PM
SCHLEIFER LEONARD SPresident & CEOJan 02Sale410.581,500615,8670Jan 05 04:56 PM
Powchik PeterSVP Clinical Development & RegJan 02Sale414.0810,8224,481,21410,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 31Option Exercise52.0325,0001,300,75035,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 19Option Exercise30.633,26499,97610,711Dec 22 12:09 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 18Option Exercise30.633,26499,97618,705Dec 19 02:11 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 17Option Exercise30.632,80085,7647,481Dec 18 04:22 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise49.076,818334,56010,556Dec 17 04:51 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrDec 16Option Exercise30.633,26499,97664,436Dec 18 04:25 PM
STAHL NEILSVP Research and Development SDec 16Option Exercise30.633,26499,9766,541Dec 18 04:25 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise30.633,26499,976503,264Dec 18 04:23 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Sale410.006,8182,795,3804,681Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Option Exercise30.631,66851,0916,049Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Sale410.761,668685,1444,681Dec 17 04:51 PM